Logo

Glenmark launches Remogliflozin + Vildagliptin + Metformin as Fixed Dose Combination for the Treatment of Type 2 Diabetes in India

Share this
Glenmark launches Remogliflozin + Vildagliptin + Metformin as Fixed Dose Combination for the Treatment of Type 2 Diabetes in India

Tuba Khan

Glenmark launches Remogliflozin + Vildagliptin + Metformin as Fixed Dose Combination for the Treatment of Type 2 Diabetes in India

Shots:

  • Glenmark has launched Remogliflozin (SGLT2 inhibitors- 100mg- ) + Vildagliptin (DPP4 inhibitors- 50mg-) + Metformin (500/1000mg) as FDC for the management of T2D in India. The FDC will be marketed under two brand names; Remo MV & Remozen MV
  • Glenmark's FDC will improve patient compliance and provide glycemic & extra glycemic benefits to patients with uncontrolled T2D at an affordable cost in India
  • The company has received DCGI’s approval for the manufacturing and marketing of the FDC in late Sep’21. Glenmark has become the first company to launch Remogliflozin (100mg) + Vildagliptin (50mg) globally as a fixed-dose combination in 2020

Click here ­to­ read full press release/ article | Ref: PR Newswire | Image: PR Newswire

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family